Tempus AI, Inc. $TEM Shares Acquired by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA increased its holdings in shares of Tempus AI, Inc. (NASDAQ:TEM) by 2,965.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 502,897 shares of the company’s stock after acquiring an additional 486,493 shares during the period. Pictet Asset Management Holding SA’s holdings in Tempus AI were worth $41,233,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Amova Asset Management Americas Inc. increased its stake in shares of Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after purchasing an additional 821,490 shares in the last quarter. Eagle Health Investments LP purchased a new position in shares of Tempus AI during the first quarter valued at approximately $11,588,000. Swiss National Bank lifted its holdings in shares of Tempus AI by 0.3% during the first quarter. Swiss National Bank now owns 183,500 shares of the company’s stock valued at $8,298,000 after purchasing an additional 600 shares during the last quarter. Aristotle Atlantic Partners LLC bought a new stake in shares of Tempus AI in the 1st quarter worth approximately $6,179,000. Finally, Teachers Retirement System of The State of Kentucky boosted its position in shares of Tempus AI by 3.4% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 125,647 shares of the company’s stock worth $5,682,000 after purchasing an additional 4,100 shares in the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Stock Down 4.6%

TEM opened at $80.54 on Wednesday. The stock has a market capitalization of $14.69 billion, a price-to-earnings ratio of -75.98 and a beta of 3.61. The firm has a 50 day moving average price of $72.08 and a 200-day moving average price of $57.40. Tempus AI, Inc. has a twelve month low of $40.77 and a twelve month high of $89.09. The company has a quick ratio of 2.48, a current ratio of 2.61 and a debt-to-equity ratio of 2.70.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Monday, November 2nd. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.16. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 47.00%. The company had revenue of $411.54 million for the quarter, compared to analysts’ expectations of $409.39 million. During the same quarter last year, the company posted ($0.46) earnings per share. The firm’s quarterly revenue was up 23.1% on a year-over-year basis. Equities research analysts forecast that Tempus AI, Inc. will post -1.20 earnings per share for the current year.

Insider Buying and Selling at Tempus AI

In other news, CEO Ryan Fukushima sold 700 shares of the stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $70.00, for a total transaction of $49,000.00. Following the transaction, the chief executive officer directly owned 15,874 shares of the company’s stock, valued at $1,111,180. This represents a 4.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric Lefkofsky sold 250,000 shares of the firm’s stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $70.36, for a total value of $17,590,000.00. Following the completion of the transaction, the chief executive officer directly owned 50,000 shares in the company, valued at $3,518,000. The trade was a 83.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 1,237,227 shares of company stock worth $85,388,983. 24.26% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently weighed in on TEM. UBS Group began coverage on Tempus AI in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $70.00 price target on the stock. Raymond James Financial set a $80.00 price objective on Tempus AI in a research note on Wednesday, September 2nd. Canaccord Genuity Group boosted their target price on Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, October 12th. Robert W. Baird increased their target price on Tempus AI from $85.00 to $92.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 3rd. Finally, Jefferies Financial Group upgraded Tempus AI from an “underperform” rating to a “hold” rating and raised their price target for the company from $35.00 to $70.00 in a report on Tuesday, November 3rd. Eleven equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $79.37.

Tempus AI Profile

Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.